{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:11:11Z","timestamp":1776838271578,"version":"3.51.2"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T00:00:00Z","timestamp":1259020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Udenafil is a phosphodiesterase 5 inhibitor used for the treatment of erectile dysfunction.<\/jats:p><jats:p>\u2022\u2003Udenafil is safe and well tolerated in healthy subjects, and effective as treatment for erectile dysfunction.<\/jats:p><jats:p>\u2022\u2003<jats:italic>In vitro<\/jats:italic> studies have demonstrated that CYP3A4 is the major enzyme responsible for the metabolism of udenafil.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003The pharmacokinetic characteristics of udenafil in the presence of ketoconazole, a potent CYP3A4 inhibitor, were determined in healthy Korean volunteers.<\/jats:p><jats:p>\u2022\u2003Systemic exposure of udenafil was significantly increased when it was administered with ketoconazole.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold> Udenafil is a phosphodiesterase 5 inhibitor used for the treatment of erectile dysfunction. It is metabolized to DA\u20108164, a major metabolite, by CYP3A4. This study was performed to investigate the effect of ketoconazole, a known CYP3A4 inhibitor, on the pharmacokinetics of udenafil.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> An open\u2010label, two\u2010period, fixed\u2010sequence crossover study was performed in 12 healthy male volunteers. They received a single 100\u2010mg oral dose of udenafil. Following a 5\u2010day interval, 400\u2003mg of ketoconazole was administered once a day for three consecutive days. On day 3 of ketoconazole treatment, a second 100\u2003mg of udenafil was dosed concomitantly. Blood samples were collected at time points up to 48\u2003h without ketoconazole treatment and up to 72\u2003h with ketoconazole co\u2010administration. The plasma concentration of udenafil was determined using liquid chromatography\u2013tandem mass spectrometry.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> Following ketoconazole co\u2010administration, the mean <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and AUC<jats:sub>last<\/jats:sub> of udenafil (95% confidence interval) increased 1.9\u2010fold (1.60, 2.27) and 3.2\u2010fold (2.82, 3.63), respectively. The median time to reach the <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> was delayed in the co\u2010administrated treatment, while the mean terminal elimination half\u2010life (<jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub>) remained relatively unchanged regardless of ketoconazole co\u2010administration. The metabolic AUC ratio (AUC<jats:sub>last<\/jats:sub> of DA\u20108164\/AUC<jats:sub>last<\/jats:sub> of udenafil) was 1.71 when udenafil was administered alone, and the value decreased to 0.19 when udenafil was dosed in the presence of ketoconazole. Regarding safety assessments, no clinically significant difference or serious adverse event was observed.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> The systemic exposure of udenafil increased significantly when it was administered with ketoconazole. Dose adjustment may be required when these drugs are used together.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2009.03601.x","type":"journal-article","created":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T11:07:23Z","timestamp":1259060843000},"page":"307-310","source":"Crossref","is-referenced-by-count":7,"title":["Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects"],"prefix":"10.1111","volume":"69","author":[{"given":"Kwang\u2010Hee","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong\u2010ju","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo\u2010Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae\u2010Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa\u2010Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo\u2010Youn","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u2010Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang\u2010Goo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung\u2010Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,2,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03107.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00723.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.11.330"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498250400010898"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(02)00397-7"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(03)00565-8"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.177"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02465.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007550717526"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01296501"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02980254"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.160-165.2002"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.020099"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005276847"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2009.03601.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2009.03601.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:44:11Z","timestamp":1697456651000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2009.03601.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,10]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1365-2125.2009.03601.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03601.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,10]]}}}